meixatech
3 hours ago
Arnold S. Lippa was the founder of Patch International, Inc. (founded in 1984) where he held the title of President & Chief Operating Officer from 1984 to 1994. He was also the founder of DOV Pharmaceutical, Inc. (founded in 1995) where he served as a Director from 2005 to 2006. He is the founder of T.Morgen Capital LLC (founded in 2005) where he currently holds the title of Senior Managing Director. Furthermore, he is the founder of Xintria Pharmaceutical Corp. (founded in 2006) where he currently serves as the Executive Chairman. Lastly, he is the founder of Atypical BioCapital Management LLC (founded in 2004) where he currently holds the title of Manager.
Dr. Lippa's current job(s) include being the Executive Chairman, President & CEO at RespireRx Pharmaceuticals, Inc. since 2013 and the President of Aurora Capital LLC since 2005.
Dr. Lippa's former job(s) include being a Director-Molecular Neurobiology at Wyeth Holdings LLC, an Independent Director at Hepion Pharmaceuticals, Inc. from 2015 to 2023, and a Professor at City University of New York and New York University School of Medicine.
I suspect RSPI is not cash starved
LTListener
5 hours ago
It is too hard to predict exactly how this would trade.
Depends on if back on the OTC or are they possibly looking at some M&A to get off the OTC and on a more institutional exchange like NASDAQ? Without any filings we dont know where fully diluted status could be either. I roughly thought around 1.5 billion shares, but could be more with any additional small financings, could be less if the convertibles are somehow bought out in whatever structure the assets land in.
Supposedly the OSA program is independently valued at 20+ million and possibly "multiples" of that. We can speculate what a phase 2 SCI drug is worth, especially with DOD funding the clinical. As well as what KRM-ll-81 could be worth at phase1 stage for epilepsy, and possibly pain indications as well especially with grant funding. For a stock like this with 3 platforms at clinical stage with really a robust history of preclinical and clinical efforts, well IMO these are very valuable now heading into clincals. 3 pennies, 5 or 10+ pennies all plausible. I think the bigger valuation leap comes in 2026-2027 as results of clinical efforts come in and obviously need to be positive results. I'll keep a majority of my stack for that risk v reward scenario.
One woud have to assume that they understand the potential lost opportunities from collaborations and resources and impact of time erosion on assets with a non-chalant do nothing time period. Frustrating as an investor.
LTListener
1 day ago
I am sure investors and all stakeholders alike are not looking for excuses and explanations. It is only logical and the significant progress/position of their platforms and the CEO comments about opening "purse strings" and all their commentary in past filings... logical that they went silent to get their house in order and that includes handling the debt, structuring the assets and negotiating with funding sources including BP.
As Catpole suggests, quite possibly there is an NDA or some type of silence agreement in play. At this point that is a logical assumption and a very good thing for shareholders as when they come out of this there is likely to be funding and resources in place to take these assets from say 50-100 million valuation to 5x that upon success in any of the upcoming clinical trials.
Yet this move to the expert market, dancing around filing responsibilites, lack of any updates and proper communication and presentation, etc, etc... well they should know by now what investors and stakeholders think of that strategy... Get this train on the rails and lets see these drugs flourish in clinicals!!
meixatech
1 day ago
macroaxis.com:
"The fear of missing out, i.e., FOMO, can cause potential investors in RespireRX Pharmaceuticals to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying RespireRX because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money."
loanranger
2 days ago
"In particular, we were highly dependent on Timothy L. Jones, our CEO and President who resigned effective January 31, 2022, and are highly dependent on Arnold S. Lippa, Ph.D., Interim CEO and Interim President, since the resignation of Mr. Jones, who is our Chief Scientific Officer and Executive Chairman, and Jeff E. Margolis, our Senior Vice President, Chief Financial Officer, Treasurer and Secretary."
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000849636/000149315222010053/form10-k.htm
LTListener
2 days ago
Wondering...
Given all the progress of 3 different platforms now at various clinical trial stages AND all the past commentary about their assets/pipeline, etc...
What do the insiders and executives think RSPI is worth today?
Less than 1 million trading on this EM?
~5 million like the 2024 price peak?
20-40 million suggested as what solely the OSA program is worth?
100+ million with government funding multiple trials on 3 different clinical stage platforms?
How do you factor in distinguishing preclinical positive results on potential breakthrough medicine for epilepsy, pain, SCI, OSA, ADHD... huge markets with unmet needs! Billion dollar potential in a few years with positive clinical momentum??
meixatech
3 days ago
Curious: this was e-published last September, I guess officially today.
Clin Pharmacol Drug Dev . 2025 Jan;14(1):50-58.
doi: 10.1002/cpdd.1475. Epub 2024 Sep 20.
Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers
Daniel P Radin, Rok Cerne, Jeffrey M Witkin, Arnold Lippa
PMID: 39302241 DOI: 10.1002/cpdd.1475
Abstract
AMPA-type glutamate receptors (AMPARs) mediate the majority of fast excitatory synaptic transmission in the mammalian brain. Ampakines, positive allosteric modulators of AMPAR, hold significant potential for the treatment of a wide range of neurological/neuropsychiatric disorders in which excitatory synaptic transmission is compromised. Low-impact ampakines are a distinct subset of ampakines that accelerate channel opening yet minimally affect receptor desensitization, which may explain their lack of seizurogenic effects at therapeutic doses in preclinical models. CX1739 is a low-impact ampakine that has shown efficacy in preclinical studies. The current clinical study examined the tolerability and pharmacokinetics of CX1739 in healthy male volunteers in a 2-part study. Part A was a single dose escalation study (100-1200 mg, 48 patients) and Part B was a multiple dose ascending study (300-600 mg BID for 7-10 days, 32 patients). CX1739 was well tolerated up to 900 mg once daily (QD) and 450 mg twice a day, with the prominent side effects being headache and nausea. Importantly, the half-life of CX1739 was 6-9 hours, and Tmax was 1-5 hours. CX1739 Cmax and AUC were dose-proportional. These findings thus set the stage for further explorations of this drug candidate in phase 2 clinical studies.
LTListener
4 days ago
Well, I believe they valued their OSA program at around 20 million and I believe a comment was made they thought it was really multiples of that. But we have not heard a peep about that program for over a year, so who knows what is stagnating that.
I consider the ampakine program CX1739/CX717 basically as 1 compound with possible multiple indications. The SCI market is not near as big as if they potentially get these into ADHD trials. I think the ampakine platform has some negative stigma associated with past mistakes and toxicity of high impact ampakines. Hence why I think the publication effort to distinguish the difference between high and low impact ampakines. They are at phase 2 stage so that does increase the value versus preclinical stage. Regardless, having the DOD now fund a phase 2 with any success exponentially increasing value is worth a chunk of change one would imagine.
IMO, KRM-ll-81 may be the most valuable asset. Exiting preclinicals, where presumably it has shown to be superior to standard of care at preclinical stage AND with huge target markets of both pain and epilepsy, well IMO this would lean heavily towards the higher end of valuation for a preclinical drug.
Most OTC investors can name several pharma and biotech stocks that at one point traded for 100s of millions with much less of a pipeline with much less of a robust preclinical effort attached and much less of a science team behind it. And here the market cap today is less than 1 million!!!
The lack of valuing your assets and your efforts fairly surely significantly limits the ability to attract resources in terms of talent and collaborators as well as attract funding and partnerships that will be necessary to smoothly transition through the various stages of development. Constant delays, stagnation, lack of this or that only serves to devalue the assets long-term as patents eventually expire, competitors are continually developing new technology, etc, etc..
meixatech
4 days ago
Well, from what I can figure, there are at least 5 different preclinical and early clinical phase molecules. So, by AI, RSPI pipeline is worth 250 to 500 M or .25 to .50 a share. Hell, by that calculation, 1000 to 3000% profit ain't too bad! Then add the irrational exuberance ... the sky's the limit. What fun to dream!
LTListener
4 days ago
Agree. Hence why sec filings and PR, interviews, commentary are more important due diligence efforts.
Interesting though asking AI what are preclinical drugs worth...
"The valuation of a preclinical drug can range significantly, but generally falls between $15 million and $100 million depending on factors like the drug's potential therapeutic value, the stage of preclinical development, and the company's overall financial standing; with most preclinical companies being valued in the range of a Series A round, typically between $40 - $100 million. "
It probably takes a lot of patience to allow your company/assets to sit so far undervalued, yet takes the smarts to utilize the government funding programs... i.e. DOD, NIH, etc to absorb early stage costs. We can argue the merits of multiple platforms moving into clinical trials and therapeutic value, resources, etc, etc, but trading less than 1 million market cap is quite a disconnect.
LTListener
4 days ago
Always interesting as to what AI search tools can cobble together on a topic. In regards to KRM-ll-81, I think the simplest due diligence is reading the publications and watching the CEO interview from early last year. Remembering that Lippa is a scientist/researcher and not a pure CEO personality the commentary I find to be genuine and meaningful.....
Calling it a "remarkable drug" and that it works in every single animal model of pain.. Collaborating with NIH and their data shows "it works" and CEO hoping purse strings open to support development. Moved into final stages of NIH preclinicals (tier 3) and subsequently we hear of the hiring of a consultant group for managing grant funding for epilepsy indication.. Curious though the intent of the NIH preclinicals was pain mitigation based and no word on if the consultant group is also seeking grant funding for this indication as well... OR is there another interested party for KRM-ll-81 pain indication only? I do believe you can JV/license drug development for specific indications, not sure on that.
Given the history of both the ampakine platform and the OSA program as well known... The gabakine platform and a drug with superior preclinical profile could be worth a gold mine and maybe is the source of the silence here??? Either way, KRM-ll-81 coupled with the ampakine and OSA assets are severly undervalued and I expect at some point in the not too distant future these assets will be valued properly as stakeholders, insiders, retail shareholders down to patients who need these medicine advancements have so much to gain by seeing these assets be given the resources to succeed and not stagnate further. In my opinion and GLTA.
bigtalan
5 days ago
AI Overview
Learn more
The outlook for KRM-II-81 under RespireRx appears positive, with preclinical studies showing promising potential as a novel treatment for pharmacoresistant epilepsy due to its ability to suppress epileptiform activity in brain slices from patients with treatment-resistant epilepsy, alongside demonstrating significant analgesic effects with minimal side effects like sedation or tolerance development, making it a potential new drug for managing severe pain conditions as well.
Key points about KRM-II-81:
Mechanism of Action:
KRM-II-81 acts as a positive allosteric modulator of the a2/3-containing GABA receptor, enhancing its activity and leading to increased inhibitory neurotransmission, which could be beneficial in managing seizures and pain.
Preclinical efficacy:
Studies in animal models of pharmacoresistant epilepsy have shown KRM-II-81 to be effective in suppressing seizures with minimal side effects compared to standard antiepileptic drugs.
Patient tissue studies:
Research has demonstrated KRM-II-81's ability to suppress hyperactivity in cortical slices from patients with pharmacoresistant epilepsy, further supporting its potential clinical translation.
Pain management potential:
Preclinical data also indicates KRM-II-81's analgesic properties, showing significant pain relief without the associated risks of opioid dependence or respiratory depression.
Potential challenges:
Clinical trials needed:
While preclinical results are promising, further clinical trials are required to confirm efficacy and safety in human patients.
Regulatory pathway:
Navigating the regulatory process for a new drug can be complex and time-consuming.
Overall, KRM-II-81 under RespireRx holds significant potential as a new treatment option for patients with pharmacoresistant epilepsy and potentially other pain conditions based on its preclinical data demonstrating potent anti-seizure and analgesic effects with a favorable safety profile.
Structural Analogs of the GABAkine KRM-II-81 Are Orally ...
Laboratory of Antiepileptic Drug Discovery, St. ... KRM-II-81 is active in models predicting efficacy in pharmacoresistant epileps...
National Institutes of Health (NIH) (.gov)
RespireRx Pharmaceuticals Inc. Announces Publication of ...
Nov 30, 2021 โ (OTCQB: RSPI) (โRespireRxโ or the โCompanyโ), is pleased to announce that scientists associated with the Company have ...
BioSpace
RespireRx Pharmaceuticals Inc. Announces a Department of ...
May 29, 2024 โ In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM- II-81 to dr...
RespireRx
Show all
Generative AI is experimental.